A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. (Q46720231)

From Wikidata

Jump to navigation Jump to search

scientific article published in April 2008

Language	Label	Description	Also known as
English	A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.	scientific article published in April 2008

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18317968%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18317968%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

based on heuristic

inferred from title

anaplastic astrocytoma

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18317968%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

author name string

Bart Neyns

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18317968%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Eric Joosens

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18317968%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Johan Menten

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18317968%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Lionel D'Hondt

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18317968%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Fabrice Branle

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18317968%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Jan Sadones

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18317968%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Alex Michotte

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18317968%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

publication date

1 April 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18317968%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Cancer Investigation

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18317968%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

26

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18317968%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18317968%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

269-277

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18317968%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

The 2007 WHO classification of tumours of the central nervous system

1 reference

https://api.crossref.org/works/10.1080%2F07357900701708393

21 January 2018

Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report

1 reference

https://api.crossref.org/works/10.1080%2F07357900701708393

21 January 2018

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1080%2F07357900701708393

21 January 2018

Temozolomide in the treatment of recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1080%2F07357900701708393

21 January 2018

Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium

1 reference

https://api.crossref.org/works/10.1080%2F07357900701708393

21 January 2018

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

1 reference

https://api.crossref.org/works/10.1080%2F07357900701708393

21 January 2018

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

1 reference

https://api.crossref.org/works/10.1080%2F07357900701708393

21 January 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1080%2F07357900701708393

21 January 2018

CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas

1 reference

https://api.crossref.org/works/10.1080%2F07357900701708393

21 January 2018

Is protracted low-dose temozolomide feasible in glioma patients?

1 reference

https://api.crossref.org/works/10.1080%2F07357900701708393

21 January 2018

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

1 reference

https://api.crossref.org/works/10.1080%2F07357900701708393

21 January 2018

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.

1 reference

https://api.crossref.org/works/10.1080%2F07357900701708393

21 January 2018

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1080%2F07357900701708393

21 January 2018

How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience

1 reference

https://api.crossref.org/works/10.1080%2F07357900701708393

21 January 2018

Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications

1 reference

https://api.crossref.org/works/10.1080%2F07357900701708393

21 January 2018

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

1 reference

https://api.crossref.org/works/10.1080%2F07357900701708393

21 January 2018

Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results

1 reference

https://api.crossref.org/works/10.1080%2F07357900701708393

21 January 2018

Identifiers

10.1080/07357900701708393

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18317968%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18317968%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46720231&oldid=1522473554"